Table 2.
Studies of TSR vs. IBT in uveal melanoma
| Study | n | Tumor heighta) (mm) | Tumor diametera) (mm) | VA in TSR and IBT | Risk of LR in TSR and IBT |
|---|---|---|---|---|---|
| Bechrakis et al. [35] | 237 | 9.4 | 14.5 | VA > 2/200 in 61.1% TSR vs. 5.6% IBT (p < 0.0009) | NA |
| Kivela et al. [37] | 98 | 7.9 | NA | VA < 20/200 after IBT (HR = 2.38; 95% CI, 1.48–3.83; p < 0.001) | LR in IBT vs. TSR (HR = 0.02; 95% CI, 0.01–0.11; p < 0.001) |
| Caminal et al. [36] | 72 | 10.0 | 15.0 | VA < 20/200 in 46.7% TSR vs. 68.8 % IBT (p < 0.121) | LR in TSR 10.5% vs. IBT 5.7% (p < 0.602) |
| Puusaari et al. [38] | 87 | 10.8 | 13.3 | VA < 20/400 in 60% TSR (95% CI, 35–75) vs. 75% IBT (95% CI, 59–86) | 5-year LR 41% in TSR (95% CI, 17–63) vs. 7% in IBT (95% CI, 2–17) |
TSR, transscleral resection; IBT, Iodine-125 brachytherapy; VA, visual acuity; LR, local recurrence; HR, hazard ratio; CI, confidence interval; NA, not available.
a)
Mean values.